HHGP. Little PR on one of their holdings. Russ
Tuesday February 15, 12:14 pm Eastern Time
Company Press Release
Harris & Harris Group Notes Announcement of
Alliance Pharmaceutical Results of Phase 2 Cardiac
Surgery Studies With Oxygent and New Patent
NEW YORK--(BUSINESS WIRE)--February 15, 2000--Harris & Harris Group, Inc. noted today that Alliance
Pharmaceutical Corp. (NASDAQ: ALLP - news; www.allp.com) announced that it had presented preliminary efficacy results
from the three Phase 2 cardiac surgery studies with Oxygent(TM), Alliance's intravascular oxygen carrier (''blood substitute''),
at the Cambridge Healthcare Institute's Six Annual Blood Products Safety Conference in Washington, DC. Alliance also
announced the issuance of a new U.S. patent, covering Augmented Acute Normovolemic Hemodilution
(Augmented-ANH(TM)). Please see the Alliance Pharmaceutical press release for more details.
The information contained in the Alliance Pharmaceutical press release was not independently verified by Harris & Harris
Group, which takes no responsibility for its content nor for any actions that anyone may take in reaction to it.
Alliance Pharmaceutical was founded by Harris & Harris Group and was Harris & Harris Group's first private equity
investment. Harris & Harris Group owns 800,000 common shares of Alliance Pharmaceutical at a cost of $1,692,000 or
$2.12 per share.
Harris & Harris Group is a Business Development Company with 9,240,831 common shares issued and outstanding.
Detailed information about Harris & Harris Group and its holdings can be found on its Web Site on the Internet at
hhgp.com. 
This press release may contain statements of a forward-looking nature relating to future events. Shareholders are cautioned that
such statements are predictions and that actual events or results may differ significantly.
|
